PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 22, 2026Romanian Journal of Internal Medicine0 citationsOpen Access

Assessment of Interleukin-33 Levels in Patients with Familial Mediterranean Fever

View Full Paper
ADAsil DemirezenAGAslihan Avanoğlu GülerHKHazan Karadeniz

Key Points

  • The study aims to assess the relationship between serum interleukin-33 levels and clinical features of Familial Mediterranean Fever.
  • Evaluated 54 patients with Familial Mediterranean Fever and 29 healthy controls.
  • Compared demographic, clinical, and biochemical parameters, including serum IL-33 levels.
  • Analyzed differences between colchicine-responsive and colchicine-resistant patients.
  • Median serum IL-33 levels in FMF patients were higher than in controls but not significantly.
  • Colchicine-responsive patients demonstrated significantly higher IL-33 levels compared to controls.
  • No significant correlation was found between IL-33 levels and inflammatory markers.

Abstract

Abstract Background This study was designed to evaluate the relationship between serum interleukin-33 (IL-33) levels and clinical features of the disease in patients with Familial Mediterranean Fever (FMF). Methods Fifty-four patients diagnosed with FMF (28 colchicine responsive and 26 colchicine resistant) and 29 healthy controls constituted the study population. Demographic, clinical, biochemical and inflammatory parameters, as well as serum IL-33 levels of the participants, were compared. Results The mean age of FMF patients was 34.3 ± 9.8 years, and 54% were female. Colchicine-resistant patients exhibited significantly higher median CRP levels than both colchicine-responsive patients and healthy controls (median IQR: 16 30.4 mg/L, 2.9 3.4 mg/L, and 3.4 2.8 mg/L, respectively; p < 0.001). Median serum IL-33 levels were higher in FMF patients than in controls (273 387 ng/L vs. 221 179 ng/L, p = 0.06). The colchicine-responsive group had significantly higher IL-33 levels compared to the control group (287 495 ng/L vs. 221 179 ng/L, p = 0.006), while no significant difference was observed between the colchicine-resistant group and controls (257 219 ng/L vs. 221 179 ng/L, p = 0.74). No significant correlations were identified between IL-33 levels and inflammatory markers or clinical characteristics. Conclusions Serum IL-33 levels do not seem to be associated with FMF disease activity; however, the observed increase in colchicine-responsive patients may indicate an immunomodulatory or compensatory function. Further comprehensive studies are needed to elucidate the role of IL-33 in FMF pathogenesis.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Demirezen et al. (2026) studied this question.

synapsesocial.com/papers/6971bd6a642b1836717e210dhttps://doi.org/10.2478/rjim-2026-0001
Ask AI
Helpful
Bookmark
Share
View Full Paper